Vanesa Huertas Carrera
Overview
Explore the profile of Vanesa Huertas Carrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Witlox W, Grimm S, Riemsma R, Armstrong N, Ryder S, Duffy S, et al.
Pharmacoeconomics
. 2020 Nov;
39(2):171-180.
PMID: 33145711
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of lenalidomide (Revlimid), as part of the Single Technology Appraisal (STA) process, to submit evidence for the...
2.
Armstrong N, Buyukkaramikli N, Penton H, Riemsma R, Wetzelaer P, Carrera V, et al.
Health Technol Assess
. 2020 Oct;
24(51):1-220.
PMID: 33108266
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to...
3.
Pouwels X, Petersohn S, Carrera V, Denniston A, Chalker A, Raatz H, et al.
Pharmacoeconomics
. 2020 Apr;
38(6):649-651.
PMID: 32249398
No abstract available.
4.
Pouwels X, Petersohn S, Carrera V, Denniston A, Chalker A, Raatz H, et al.
Pharmacoeconomics
. 2019 Nov;
38(5):431-441.
PMID: 31701471
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN), to submit evidence on the clinical...
5.
Thielen F, Buyukkaramikli N, Riemsma R, Fayter D, Armstrong N, Wei C, et al.
Pharmacoeconomics
. 2018 Dec;
37(8):975-984.
PMID: 30547368
The National Institute for Health and Care Excellence (NICE), as part of the institute's single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit...